Stathmin 1 Antibody - #AF5414
Product: | Stathmin 1 Antibody |
Catalog: | AF5414 |
Description: | Rabbit polyclonal antibody to Stathmin 1 |
Application: | WB IHC IF/ICC |
Reactivity: | Human, Mouse, Rat |
Prediction: | Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus |
Mol.Wt.: | 17 kDa; 17kD(Calculated). |
Uniprot: | P16949 |
RRID: | AB_2837898 |
Related Downloads
Protocols
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# AF5414, RRID:AB_2837898.
Fold/Unfold
C1orf215; Lag; LAP 18; LAP18; Leukemia associated phosphoprotein p18; Leukemia-associated phosphoprotein p18; Metablastin; Oncoprotein 18; OP 18; Op18; p18; p19; Phosphoprotein 19; Phosphoprotein p19; pp17; pp19; PR22; Pr22 protein; Prosolin; Protein Pr22; SMN; Stathmin; Stathmin1; STMN 1; Stmn1; STMN1_HUMAN;
Immunogens
Ubiquitous. Expression is strongest in fetal and adult brain, spinal cord, and cerebellum, followed by thymus, bone marrow, testis, and fetal liver. Expression is intermediate in colon, ovary, placenta, uterus, and trachea, and is readily detected at substantially lower levels in all other tissues examined. Lowest expression is found in adult liver. Present in much greater abundance in cells from patients with acute leukemia of different subtypes than in normal peripheral blood lymphocytes, non-leukemic proliferating lymphoid cells, bone marrow cells, or cells from patients with chronic lymphoid or myeloid leukemia.
- P16949 STMN1_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MASSDIQVKELEKRASGQAFELILSPRSKESVPEFPLSPPKKKDLSLEEIQKKLEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTHKMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - P16949 As Substrate
Site | PTM Type | Enzyme | Source |
---|---|---|---|
A2 | Acetylation | Uniprot | |
S3 | Phosphorylation | Uniprot | |
S4 | Phosphorylation | Uniprot | |
K9 | Acetylation | Uniprot | |
K9 | Ubiquitination | Uniprot | |
R14 | Methylation | Uniprot | |
S16 | Phosphorylation | Q13153 (PAK1) , Q16566 (CAMK4) , Q13554 (CAMK2B) , P17612 (PRKACA) , Q9UQM7 (CAMK2A) | Uniprot |
S25 | Phosphorylation | P53778 (MAPK12) , P45983 (MAPK8) , P24941 (CDK2) , P27361 (MAPK3) , Q15759 (MAPK11) , P05771 (PRKCB) , P45984 (MAPK9) , O15264 (MAPK13) , P06493 (CDK1) , Q16539 (MAPK14) , P53779 (MAPK10) , P28482 (MAPK1) | Uniprot |
R27 | Methylation | Uniprot | |
S28 | Phosphorylation | Uniprot | |
K29 | Acetylation | Uniprot | |
K29 | Methylation | Uniprot | |
K29 | Ubiquitination | Uniprot | |
S31 | Phosphorylation | Uniprot | |
S38 | Phosphorylation | Q00535 (CDK5) , O15264 (MAPK13) , P45983 (MAPK8) , Q8TAS1 (UHMK1) , Q13153 (PAK1) , P05771 (PRKCB) , P06493 (CDK1) , P28482 (MAPK1) , P53779 (MAPK10) , P24941 (CDK2) , P45984 (MAPK9) , P27361 (MAPK3) | Uniprot |
K41 | Ubiquitination | Uniprot | |
K43 | Ubiquitination | Uniprot | |
S46 | Phosphorylation | Uniprot | |
K52 | Acetylation | Uniprot | |
K52 | Ubiquitination | Uniprot | |
K53 | Acetylation | Uniprot | |
K53 | Ubiquitination | Uniprot | |
K62 | Ubiquitination | Uniprot | |
S63 | Phosphorylation | P17612 (PRKACA) | Uniprot |
K70 | Acetylation | Uniprot | |
K70 | Ubiquitination | Uniprot | |
K75 | Ubiquitination | Uniprot | |
K80 | Acetylation | Uniprot | |
K80 | Ubiquitination | Uniprot | |
K85 | Ubiquitination | Uniprot | |
S94 | Phosphorylation | Uniprot | |
K95 | Acetylation | Uniprot | |
K95 | Ubiquitination | Uniprot | |
K100 | Acetylation | Uniprot | |
K100 | Ubiquitination | Uniprot | |
T102 | Phosphorylation | Uniprot | |
K104 | Acetylation | Uniprot | |
K104 | Ubiquitination | Uniprot | |
K109 | Acetylation | Uniprot | |
K119 | Acetylation | Uniprot | |
K119 | Ubiquitination | Uniprot | |
K128 | Acetylation | Uniprot | |
K128 | Ubiquitination | Uniprot | |
R134 | Methylation | Uniprot | |
K137 | Acetylation | Uniprot | |
K137 | Ubiquitination | Uniprot | |
K140 | Ubiquitination | Uniprot | |
T146 | Phosphorylation | Uniprot |
Research Backgrounds
Involved in the regulation of the microtubule (MT) filament system by destabilizing microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear (By similarity).
Many different phosphorylated forms are observed depending on specific combinations among the sites which can be phosphorylated. MAPK is responsible for the phosphorylation of stathmin in response to NGF. Phosphorylation at Ser-16 seems to be required for neuron polarization (By similarity). Phosphorylation at Ser-63 reduces tubulin binding 10-fold and suppresses the MT polymerization inhibition activity.
Cytoplasm>Cytoskeleton.
Ubiquitous. Expression is strongest in fetal and adult brain, spinal cord, and cerebellum, followed by thymus, bone marrow, testis, and fetal liver. Expression is intermediate in colon, ovary, placenta, uterus, and trachea, and is readily detected at substantially lower levels in all other tissues examined. Lowest expression is found in adult liver. Present in much greater abundance in cells from patients with acute leukemia of different subtypes than in normal peripheral blood lymphocytes, non-leukemic proliferating lymphoid cells, bone marrow cells, or cells from patients with chronic lymphoid or myeloid leukemia.
Binds to two alpha/beta-tubulin heterodimers. Interacts with KIST.
Belongs to the stathmin family.
Research Fields
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Human Diseases > Cancers: Overview > MicroRNAs in cancer.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.